Skip to main content Skip to section navigation Skip to footer
Partnering Careers
IMV Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • DPX Delivery Platform
    • Overview
    • Scientific Materials
  • Pipeline
    • Overview
    • Maveropepimut-S
    • Expanded Access
  • News & Media
    • Press Releases
    • Events
    • Email Alerts
  • Investors
    • Overview
    • Press Releases
    • Events, Webcasts & Presentations
    • Financial Info
    • Stock Data
    • Filings
    • Governance
    • Contacts
    • FAQ
  • Contact
    • Get in Touch
    • Safety & Respect
  • Partnering
  • Careers

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events, Webcasts & Presentations
    • Overview
    • IR Calendar
    • Presentations
    • Scientific Materials
    • Email Alerts
  • Financial Info
    • Financial Results
    • Tax Information
    • Proxy Information
    • Stock Option Plan
    • Deferred Share Unit Plan
  • Stock Data
    • NASDAQ: IMV
    • TSX: IMV
    • Analyst Coverage
  • Filings
    • SEC Filings
    • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contacts
  • FAQ
Mar 10, 2022 7:05am EST

IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, 2022

Mar 09, 2022 7:05am EST

IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022

Feb 17, 2022 7:05am EST

IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform

Jan 12, 2022 7:05am EST

IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL

Jan 05, 2022 7:05am EST

IMV Inc. to Present at Two Upcoming Investor Events

Dec 22, 2021 7:05am EST

IMV Appoints Andrew Hall as Chief Executive Officer

Dec 21, 2021 7:05am EST

IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts

Dec 20, 2021 7:05am EST

IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility

Dec 02, 2021 7:05am EST

Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress

Nov 30, 2021 7:05am EST

IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer

  • Previous Pagearrow_back
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • …Page 42
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Visit us on Youtube

    Youtube

© IMV Inc. All Rights Reserved.
Privacy Policy Terms of Use Sitemap Manage Cookie Preferences